JEAC (at daily doses of 5, 10, and 20 g/kg, i.g. for 14 days) has also been proven to considerably decrease FBG levels, blood glucose, area under the curve, LDH, glucagon (GC), and pyruvate in serum and increase fasting insulin (FINS) levels in STZ-induced diabetic mice, indicating that this extract could lessen hyperglycemia and hyperlipidemia, suppressing DN progression and development; it is a potential candidate agent for treating or preventing DN (Yang et al., 2019a). The gene discussed is GC; the disease is liver dysplastic nodule.